“I have been working with CRT reagents since 1992, when I started my first company, NeoMarkers Inc. I worked closely with CRT reagents and over a period of nine years licensed 100 hybridoma’s from their portfolio. In total, I had collated my own portfolio of over 1500 hybridoma’s from around the world.
NeoMarkers was bought by ThermoFisher in 2002. Ten years later (2012), I have started a new business, NeoBiotechnologies, Inc., to work with technology transfer offices around the world. I currently work with CRT reagents (Ximbio) to identify new hybridomas to license that can lead to new products of NeoBiotechnologies. Some hybridoma’s are for similar targets of interest, but I choose Ximbio reagents over competitors because they are generated in prestigious laboratories and are well published. Some clones are also exclusive to Ximbio and cannot be found elsewhere. My mission is to have a large portfolio of hybridomas against human proteome.
I have recommended Ximbio to a number of the companies I work with, due to the professional, friendly, responsive service, and the quality of Ximbio reagents. The hybridomas are mycoplasma-free, and there are plenty of viable cells that usually do not require sub-cloning. The Ximbio team is well informed about the reagents and the licencing process is extremely efficient.”
